Key statistics
On Friday, Xilio Therapeutics Inc (XLO:NSQ) closed at 0.892, 82.04% above the 52 week low of 0.49 set on Dec 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.91 |
---|---|
High | 0.94 |
Low | 0.87 |
Bid | 0.88 |
Offer | 0.95 |
Previous close | 0.92 |
Average volume | 173.96k |
---|---|
Shares outstanding | 43.96m |
Free float | 25.97m |
P/E (TTM) | -- |
Market cap | 40.44m USD |
EPS (TTM) | -1.72 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
- Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
- Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
- Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
More ▼